Futures Mixed Ahead...
Health Care: Drugs
ViroPharma Inc. (VPHM: NASDAQ)
$29.00 0.31 | 1.08%
06/19/13 - 01:30 PM ET
Portfolios with VPHM
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ProJoel Greenblatt - Gotham Ca...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Userjohnnystocks
- ContributorEarnings Short Squeeze Play...
- UserGFNN Stockdiagnostics 3
- ContributorEarnings Short Squeeze Play...
- ContributorStocks At New 52-Week Highs...
- UserStocks
Latest VPHM Headlines from TheStreet
- 4 Stocks Spiking on Big Volume 05.28.13 | 10:05 pm
- ViroPharma (VPHM) Shares Cross Above 200 DMA 05.13.13 | 12:05 pm
- 'Mad Money' Lightning Round: Buy More Travelers 04.18.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Haves and Have-Nots 04.17.13 | 08:04 pm
- Bullish Two Hundred Day Moving Average Cross - VPHM 04.12.13 | 05:04 pm
- Cramer's 6 Stocks in 60 Seconds: TRLA LULU EOG BDX CMG VPHM (Update1) 03.27.13 | 05:03 pm
- Cramer's Top Stock Picks: WPRT VPHM TXN JDSU CSC 03.09.13 | 06:03 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 03.08.13 | 07:03 pm
- ViroPharma Inc. Stock Downgraded (VPHM) 11.19.12 | 04:11 am
- 8 Stocks Soaring Higher With Big Volume 09.21.12 | 02:09 pm
Press Releases for VPHM
- ViroPharma Receives Orphan Drug Designation For Maribavir In Europe - PR Newswire 06.11.13 | 03:06 am
- ViroPharma To Participate In Several June Healthcare Investor Conferences - PR Newswire 05.31.13 | 02:05 pm
- Subgroup Analyses Of Pivotal And Open Label Prevention Trials Showed Effectiveness Of ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) In Prevention Of Angioedema Attacks In Patients With Hereditary Angioedema (HAE) Poorly Controlled On Anabolic Androgens - PR Newswire 05.28.13 | 07:05 am
- ViroPharma To Participate In Two May Healthcare Investor Conferences - PR Newswire 05.09.13 | 05:05 pm
- ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013 - PR Newswire 04.25.13 | 12:04 pm
- ViroPharma To Release 2012 Fourth Quarter And Full Year Financial Results On February 27, 2013 - PR Newswire 02.22.13 | 12:02 pm
- ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences - PR Newswire 02.11.13 | 12:02 pm
- Sub-Group Analysis Of Data From Pediatric Patients With Hereditary Angioedema Published In The Journal Of Pediatrics - PR Newswire 01.16.13 | 08:01 am
- ViroPharma Provides 2013 Outlook - PR Newswire 01.07.13 | 07:01 am
- ViroPharma And Halozyme Therapeutics Announce Initiation Of Phase 2b Dose Ranging Combination Study For Subcutaneous Administration Of Cinryze® (C1 Esterase Inhibitor [human]) With Hyaluronidase (rHuPH20) - PR Newswire 12.19.12 | 07:12 am
Partner Headlines for VPHM
- Top Mutual Funds Still Nibbling At Ocwen Financial - Investor's Business Daily 02.04.13 | 06:02 pm
- Pertaining to Relief for ViroPharma - Analyst Blog - NASDAQ 09.25.12 | 07:09 pm
- Abbott-Astellas Collaborate - Analyst Blog - Zacks 09.13.12 | 06:09 pm
- ViroPharma Misses Zacks Estimates - Analyst Blog - Zacks 08.10.12 | 09:08 am
- VPHM Manufacturing Process Approved - Analyst Blog - Zacks 08.07.12 | 07:08 pm
- ViroPharma Receives FDA Approval of Cinryze - Benzinga 08.06.12 | 01:08 pm
- Bad News for ViroPharma - Analyst Blog - Zacks 08.03.12 | 06:08 pm
- ViroPharma's Cinryze® (C1 esterase inhibitor [human]) Open Label Prophylaxis Study Showed Up To 2.6 Years Of Effectiveness In Majority Of Subjects - Benzinga 07.27.12 | 09:07 am
- ViroPharma Initiates Phase II Study - Analyst Blog - Zacks 06.05.12 | 07:06 pm
- ViroPharma Falters, Guides Lower - Analyst Blog - Zacks 05.02.12 | 10:05 am
